Seven of 12 patients must each clear two simultaneous bars at their 12-month assessment for Rocket’s pivotal Danon disease trial to succeed, and that endpoint structure now has FDA backing. The company reported third-quarter results on November 12, disclosing that the agency has aligned on the full design of the global pivotal Phase 2 study of RP-A501: a recalibrated dose, a 12-patient efficacy population, and co-primary endpoints requiring both myocardial LAMP2 expression at Grade 1 or higher and a 10-percent or greater reduction in left ventricular mass index from baseline. Those endpoints are intended to support an accelerated approval pathway, and Rocket expects to finish dosing by mid-2027 with topline results in mid-2028.
The trial’s first three patients, dosed under the modified protocol, count toward that 12-patient population, and October safety observations from those patients were described as encouraging. Danon disease is an ultra-rare X-linked disorder driven by LAMP2 mutations; Rocket’s independent epidemiological analyses put the U.S. prevalence at 10,000 to 11,000 people, including roughly 4,000 males, and the company says it has identified more than 900 patients. The prevalence figure includes undiagnosed and asymptomatic individuals, so it does not translate directly into a treatable pool, but it does illustrate how few patients any single trial must capture to be pivotal. Danon disease has no well-established standard of care, which is what makes the accelerated pathway consequential here.
Rocket also started dosing in the Phase 1 trial of RP-A701 for BAG3-associated dilated cardiomyopathy, an eight-patient dose-escalation study running through mid-2029 that evaluates safety, biological activity, and preliminary efficacy including cardiovascular function. The European Commission granted RP-A701 orphan designation in October. Meanwhile, the company’s KRESLADI gene therapy for leukocyte adhesion deficiency reached commercial readiness on October 1, with two Qualified Treatment Centers activated for patient onboarding. On the balance sheet, cash and investments stood at $279.4 million as of September 30, covering operations into the third quarter of 2028; the full $150 million Hercules credit facility, of which $35 million was drawn at close, could stretch that runway into 2029 depending on draw timing and spending.
The number to watch is the mid-2028 Danon topline readout. That is when investors will find out whether the dual-endpoint threshold, seven of 12 patients clearing both LAMP2 expression and LV mass index criteria simultaneously, holds up in a disease this rare.
Source link: https://www.sec.gov/Archives/edgar/data/1281895/000114036126043434/ef20085455_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
